Tildrakizumab 200 mg

DRUG2 trials

Sponsors

Sun Pharmaceutical Industries Limited

Conditions

Plaque Psoriasis

Phase 3

A Study to Evaluate the Efficacy and Safety of Subcutaneous MK-3222, Followed by an Optional Long-Term Safety Extension Study, in Participants With Moderate-to-Severe Chronic Plaque Psoriasis (MK-3222-010)

CompletedNCT01722331

Sun Pharmaceutical Industries LimitedPlaque Psoriasis

Start: 2012-12-06End: 2021-11-10Updated: 2022-03-23

A Study to Evaluate the Efficacy and Safety/Tolerability of Subcutaneous Tildrakizumab (SCH 900222/MK-3222) in Participants With Moderate-to-Severe Chronic Plaque Psoriasis Followed by a Long-term Extension Study (MK-3222-011)

CompletedNCT01729754

Sun Pharmaceutical Industries LimitedPlaque Psoriasis

Start: 2013-02-05End: 2021-10-26Updated: 2022-03-08

Related Papers

Efficacy and Safety of Tildrakizumab for Moderate-to-Severe Plaque Psoriasis with Diabetes: Pooled Subgroup Analysis of reSURFACE 1 and reSURFACE 2

Dermatology and Therapy2026-03-16

Efficacy and safety of tildrakizumab in patients with early- vs. late-onset psoriasis

British Journal of Dermatology2025-05-133 citations

Efficacy of Tildrakizumab Across Different Body Weights in Moderate-to-Severe Psoriasis Over 5 Years: Pooled Analyses from the reSURFACE Pivotal Studies

Dermatology and Therapy2022-09-1312 citations

Tildrakizumab efficacy and safety in patients with psoriasis and concomitant metabolic syndrome: <i>post hoc</i> analysis of 5‐year data from <scp>reSURFACE</scp> 1 and <scp>reSURFACE</scp> 2

Journal of the European Academy of Dermatology and Venereology2022-04-2320 citations

Five-year efficacy and safety of tildrakizumab in patients with moderate-to-severe psoriasis who respond at week 28: pooled analyses of two randomized phase III clinical trials (reSURFACE 1 and reSURFACE 2).

2021-05-0462 citations

Efficacy and safety of tildrakizumab in Japanese patients with moderate to severe plaque psoriasis: Results from a 64‐week phase 3 study (reSURFACE 1)

The Journal of Dermatology2021-02-2511 citations

Long‐term efficacy and safety of tildrakizumab in Japanese patients with moderate to severe plaque psoriasis: Results from a 5‐year extension of a phase 3 study (reSURFACE 1)

The Journal of Dermatology2021-02-0114 citations

Tildrakizumab efficacy, drug survival, and safety are comparable in patients with psoriasis with and without metabolic syndrome: Long-term results from 2 phase 3 randomized controlled studies (reSURFACE 1 and reSURFACE 2).

2020-09-1922 citations

Clearance of head and neck involvement in plaque psoriasis with tildrakizumab treatment in the phase 3 reSURFACE 1 study

Journal of the European Academy of Dermatology and Venereology2020-05-2011 citations

Disease activity and treatment efficacy using patient-level Psoriasis Area and Severity Index scores from tildrakizumab phase 3 clinical trials.

2020-04-3017 citations

Exposure–response characterisation of tildrakizumab in chronic plaque psoriasis: Pooled analysis of 3 randomised controlled trials

British Journal of Clinical Pharmacology2020-03-127 citations

Efficacy of tildrakizumab by patient demographic and disease characteristics across a phase 2b and 2 phase 3 trials in patients with moderate‐to‐severe chronic plaque psoriasis

Journal of the European Academy of Dermatology and Venereology2020-01-1019 citations

Population-Pharmacokinetic Modeling of Tildrakizumab (MK-3222), an Anti-Interleukin-23-p19 Monoclonal Antibody, in Healthy Volunteers and Subjects with Psoriasis.

2019-08-017 citations

Long-term efficacy and safety of tildrakizumab for moderate-to-severe psoriasis: pooled analyses of two randomized phase III clinical trials (reSURFACE 1 and reSURFACE 2) through 148 weeks.

2019-07-18109 citations

Sustained and continuously improved efficacy of tildrakizumab in patients with moderate-to-severe plaque psoriasis

Journal of Dermatological Treatment2019-07-0313 citations

Tildrakizumab versus placebo or etanercept for chronic plaque psoriasis (reSURFACE 1 and reSURFACE 2): results from two randomised controlled, phase 3 trials.

2017-06-06400 citations